Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa

被引:456
作者
Coetzee, D
Hildebrand, K
Boulle, A
Maartens, G
Louis, F
Labatala, V
Reuter, H
Ntwana, N
Goemaere, E
机构
[1] Univ Cape Town, Sch Publ Hlth & Family Med, Infect Dis Epidemiol Unit, ZA-7925 Observatory, South Africa
[2] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa
关键词
antiretroviral therapy; primary care; CD4 cell count; HIV RNA viral load; South Africa;
D O I
10.1097/00002030-200404090-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: A community-based antiretroviral therapy (ART) programme was established in 2001 in a South African township to explore the operational issues involved in providing ART in the public sector in resource-limited settings and demonstrate the feasibility of such a service. Methods: Data was analysed on a cohort of patients with symptomatic HIV disease and a CD4 lymphocyte count < 200 X 10(6) cells/l The programme used standardized protocols (using generic medicines whenever possible), a team-approach to clinical care and a patient-centred approach to promote adherence. Results: Two-hundred and eighty-seven adults naive to prior ART were followed for a median duration of 13.9 months. The median CD4 lymphocyte count was 43 X 106 cells/l at initiation of treatment, and the mean log(10) HIV RNA was 5.18 copies/ml. The HIV RNA level was undetectable (< 400 copies/ml) in 88.1, 89.2, 84.2, 75.0 and 69.7% of patients at 3, 6, 12, 18 and 24 months respectively. The cumulative probability of remaining alive was 86.3% at 24 months on treatment for all patients, 91.4% for those with a baseline CD4 lymphocyte count greater than or equal to 50 X 10(6) cells/l, and 81.8% for those with a baseline CD4 lymphocyte count < 50 X 10(6) cells/l. The cumulative probability of changing a single antiretroviral drug by 24 months was 15.1% due to adverse events or contraindications, and 8.4% due to adverse events alone. Conclusions: ART can be provided in resource-limited settings with good patient retention and clinical outcomes. With responsible implementation, ART is a key component of a comprehensive response to the epidemic in those communities most affected by HIV. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:887 / 895
页数:9
相关论文
共 24 条
  • [1] Abdullah MF, 2001, S AFR MED J, V91, P579
  • [2] [Anonymous], 1990, WEEKLY EPIDEMIOL REC, V65, P221
  • [3] Confronting global AIDS: Prevention and treatment
    Berkman, A
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2001, 91 (09) : 1348 - 1349
  • [4] A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study
    Carr, A
    Chuah, J
    Hudson, J
    French, M
    Hoy, J
    Law, M
    Sayer, D
    Emery, S
    Cooper, DA
    [J]. AIDS, 2000, 14 (09) : 1171 - 1180
  • [5] Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P185
  • [6] Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States
    Chan, KCW
    Yip, B
    Hogg, RS
    Montaner, JSG
    O'Shaughnessy, MV
    [J]. AIDS, 2002, 16 (12) : 1693 - 1695
  • [7] *CIT CAP TOWN DEP, 2002, TUB SERV REV KHAYEL
  • [8] DARKOHAMPEM E, 2002, SCALING ANTIRETROVIR
  • [9] Dorrington R, 2002, POPULATION PROJECTIO
  • [10] Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies
    Egger, M
    May, M
    Chêne, G
    Phillips, AN
    Ledergerber, B
    Dabis, F
    Costagliola, D
    Monforte, AD
    de Wolf, F
    Reiss, P
    Lundgren, JD
    Justice, AC
    Staszewski, S
    Leport, C
    Hogg, RS
    Sabin, CA
    Gill, MJ
    Salzberger, B
    Sterne, JAC
    [J]. LANCET, 2002, 360 (9327) : 119 - 129